多靶点粪便FIT-DNA检测技术在结直肠癌患者、配偶及一级亲属筛查中的应用研究

Application of multitarget stool FIT-DNA test for cancer screening in colorectal cancer patients and their spouses and first-degree relatives

目的初步探究多靶点粪便FIT-DNA检测技术对结直肠癌筛查的有效性,同时探索结直肠癌患者配偶及其一级亲属的结直肠癌及癌前病变发病风险。方法采用新型多靶点粪便FIT-DNA联合检测技术对于2017年4月至2019年3月全国八家医院的结直肠外科或普外科就诊的结直肠癌患者、患者配偶及一级亲属进行检测,并结合肠镜结果评价其检测性能。结果共211名受试者均完成多靶点粪便FIT-DNA联合检测及肠镜检查,其中135例为结直肠癌患者(64.0%),47例为患者配偶(22.3%),29例为患者一级亲属(13.7%)。其中,患者配偶的肠镜病变检出率为14.9%(7/47),患者一级亲属的肠镜病变检出率为24.1%(7/29),均未有癌变检出。多靶点粪便FIT-DNA联合检测技术检测结直肠癌的敏感性为89.6%(121/135),特异度为96.8%(60/62)。结论本研究初步肯定了多靶点粪便FIT-DNA联合检测技术在结直肠癌筛查中的检测性能,为进一步开展大样本前瞻性研究奠定了良好的基础。

Objective To assess the clinical performance of Multitarget stool FIT-DNA test for colorectal cancer(CRC)screening,and investigate the risk factors of developing colorectal cancer and precancerous lesions in spouses and first-degree relatives of CRC patients.Methods CRC patients and their spouses and first-degree relatives were recruited from colorectal surgery or general surgery departments of eight hospitals in China between April 2017 to March 2019.Multitarget stool FIT-DNA test results were compared with colonoscopy outcomes.Results Of 211 valid participants,135(64.0%)were colorectal cancer patients,47(22.3%)were spouses and 29(13.7%)were first-degree relatives.Colonoscopy revealed14.9%(7/47)of spouses and 24.1%(7/29)of first-degree relatives had colonoscopic lesions.The sensitivity and specificity of Multitarget stool FIT-DNA test were 89.6%(121/135)and 96.8%(60/62)respectively.Conclusion The study confirmed the clinical performance of Multitarget stool FIT-DNA test in CRC screening,and provided essential data for large scale prospective study in the next stage.